Recent Quotes (30 days)

You have no recent quotes
chg | %

Premaitha Health PLC news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

NIPT 9.00 -0.12 (-1.37%)
price chart
Premaitha Health
Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA� uses complex statistical analysis to determine the likelihood that a fetus is carrying... hardman & co. Premaitha Health PLC. Premaitha ...
Premaitha Health PLC Premaitha Health signs Investment Agreement with Thermo ...
Premaitha's CE-marked, non-invasive prenatal screening (NIPT) product, the IONA� test, runs on Thermo Fisher's two sequencing instruments, the Ion Proton and Ion Chef.
Manchester's Premaitha Health wins �5m backing from science giant  Manchester Evening News
Premaitha Health PLC bags tenth customer
Premaitha Health PLC (LON:NIPT) has landed a tenth customer for its IONA diagnostic, Europe's first CE-marked non-invasive DNA-based pre-natal test for Down's Syndrome.
Shares Of Premaitha Health Plc (LON:NIPT) Rated As Buy By Analysts At ...  Risers & Fallers
Premaitha Health PLC 134.1% Potential Upside Indicated by Panmure Gordon
Premaitha Health PLC with EPIC/TICKER LON:NIPT had its stock rating noted as 'Retains' with the recommendation being set at 'BUY' this morning by analysts at Panmure Gordon.
FinnCap Reiterates "Corporate" Rating for Premaitha Health PLC (NIPT)  Web Breaking News
Premaitha Health Plc Solid first year IONA sales; positive litigation update
Hardman & Co Report Premaitha Health Plc (LON:NIPT) uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests.
Premaitha Health PLC (NIPT) Given "Corporate" Rating at FinnCap  The Vista Voice
Premaitha Health Plc retained as Buy By Panmure Gordon  Risers & Fallers
PEG Ratio (5 yr expected):
Premaitha Health PLC, a molecular diagnostic company, develops tests for non-invasive prenatal screening and other applications in the United Kingdom.
Analyst Coverage Updates - Premaitha Health (LON:NIPT)
Premaitha Health PLC, formerly ViaLogy plc, is engaged in molecular diagnostics business for research, and the development and commercialization of gene analysis techniques.
Premaitha Health to join AIM as it prepares to launch first product
Subject to ViaLogy shareholders approval later this month, the enlarged business will be re-named Premaitha Health PLC and will become a listed company on the AIM platform.
ViaLogy Buys Molecular Diagnostic Company But Struggles To  London South East
New Down's syndrome test likely after pharma reverse takeover  Financial Times
Related articles »  
Recent Research Analysts' Ratings Updates for Premaitha Health PLC (NIPT)
3/29/2016 - Premaitha Health PLC had its “buy” rating reaffirmed by analysts at Panmure Gordon. They now have a GBX 24 ($0.34) price target on the stock.
Premaitha Health (LON:NIPT) New Price Targets
Premaitha Health PLC, formerly ViaLogy plc, is engaged in molecular diagnostics business for research, and the development and commercialization of gene analysis techniques.